Abbott 2Q26 EPS beat and guidance raised, with management emphasizing no sign of slowing medtech demand

Overview

This report reviews Abbott Laboratories' 2Q26 results. Revenue was broadly in line with market expectations, while EPS modestly beat expectations and full-year EPS guidance was raised. Bernstein believes that although investors are concerned about slower hospital procedure volumes and medtech demand in the second half, Abbott management strongly pushed back using evidence from Diagnostics, Cardiovascular, and the Medicare reimbursement mix, emphasizing that demand in medtech and diagnostics remains resilient.

Core views

The core views are: first, 2Q26 revenue quality was stable, with all major business segments overall performing relatively well versus expectations, while EPS was driven by better-than-expected gross margin; second, 2H26 comparable growth is expected to accelerate to about 8.7%, mainly contributed by Nutrition, Electrophysiology, Core Lab, and Cancer Diagnostics; third, management views concerns about slowing medtech demand as overdone, and Abbott has not seen meaningful weakness in procedure or testing volumes; fourth, EP, Diabetes Care, Cancer Diagnostics, and Nutrition all have follow-on catalysts at the product, reimbursement, or execution level; fifth, Structural Heart and Rapid/Molecular Diagnostics remain near-term pressure points.

Analysis framework

The report uses a combination of earnings breakdown, consensus comparison, interpretation of management commentary from the conference call, analysis of business-line growth drivers, and a relative valuation framework, with a focus on assessing 2Q26 actual results, changes to FY26 guidance, second-half growth visibility, and risks to medtech market demand.

Methodology notes

• Valuation methodsforward p/e multiple

  Forward P/E target multiple valuation

  Bernstein uses a target P/E multiple of 19x, raised from 18x previously to reflect greater confidence in growth forecasts, and applies it to Q5-Q8 forward EPS of $6.16 to derive a $117 target price.

• earnings_reviewbeat and raise

  Earnings beat and guidance raise

  The report compares 2Q26 revenue, EPS, gross margin, and segment sales against market consensus expectations, and assesses the impact of the full-year EPS guidance raise on the investment view.

• industry_demand_checkdiagnostics as barometer

  Using diagnostics testing volumes as a forward indicator of healthcare demand

  Management views Diagnostics, especially Hospital Labs and Core Lab testing volumes, as leading indicators of healthcare activity and procedure demand, using them to rebut concerns about slowing medtech demand.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• ABT.US

  Research target

  Strengths

  Diversified business mix, resilient demand in medical devices and diagnostics, EPS beat, higher FY26 EPS guidance, and strong growth momentum in EP and Cancer Diagnostics.

  Weaknesses

  Nutrition is still declining year over year, Structural Heart is affected by competitive pressure in U.S. mitral valve, Diabetes Care growth has slowed from historical highs, and Rapid and Molecular Diagnostics are being dragged down by weak respiratory testing demand.

  Comparison

  Compared with medtech demand concerns triggered by HCA's preannouncement, both Abbott and JNJ said they have not seen slowing in underlying surgery or procedure markets.

  Risks

  If hospital procedure volumes, Medicare-related procedures, CGM share, Structural Heart recovery, or China Core Lab demand fall short of expectations, the target price and earnings forecasts may come under pressure.

• Medtech stocks

  Industry sentiment mapping

  Strengths

  Abbott management's positive comments on the health of the medtech market help ease concerns about industry demand.

  Weaknesses

  The industry is still affected by hospital procedure volume data, changes in payer mix, and policy expectations.

  Comparison

  HCA's preannouncement caused medtech stocks to fall 3%-7%, after which comments from Abbott and other companies helped drive a rebound in related stocks.

  Risks

  If subsequent data from hospitals, insurers, or device companies confirm slowing procedure volumes, the industry's valuation recovery could reverse.

Key data

• 2Q26 revenue12.59bn USD, comparable growth of 4.8%0.4% above market expectations of 12.54bn USD.
• 2Q26 adjusted EPS1.31 USD3 cents above market expectations of 1.28 USD, a 2.6% beat.
• 2Q26 adjusted gross margin58.0%About 50 bps above market expectations.
• FY26 comparable sales growth guidance6.5%-7.5%The company maintained its full-year organic or comparable growth guidance.
• FY26 adjusted diluted EPS guidance5.45-5.60 USDPreviously 5.38-5.58 USD, with the midpoint raised by 4.5 cents.
• Medical Devices5.9bn USD, comparable growth of 8.4%0.6% above market expectations; Electrophysiology, Rhythm Management, Heart Failure, and Vascular were highlights.
• Diagnostics3.09bn USD, comparable growth of 2.9%1.6% above market expectations; Core Lab was strong, while Rapid and Molecular Diagnostics were dragged down by weak respiratory virus testing demand.
• Nutrition2.14bn USD, comparable decline of 3.6%About 1% above market expectations, with management saying the business is progressing as planned.
• Established PharmaceuticalsAbout 1.50bn USD, comparable growth of 8.7%1.2% above market expectations of 1.48bn USD, with broad-based growth in India, Latin America, and Southeast Asia.
• Target price and upside117.00 USD, implied upside of 18%Closing price was 98.83 USD on July 16, 2026.

Impact & implications

In terms of investment implications, the report reinforces ABT's combination of defensiveness and growth as a medtech and diversified healthcare products company. The EPS beat, raised guidance, and management's confidence in second-half acceleration support the target price increase; at the same time, if market concerns about slowing medtech procedure volumes ease, sentiment toward ABT and related medtech stocks may continue to recover. The key near-term debate is whether 2H26 growth acceleration can be delivered, and whether Structural Heart, Diabetes Care share, and China VBP pressure can improve as management expects.

Risks

• Medtech surgery volumes or procedure demand actually slow in 2H26, weakening management's view on market health.
• Competitive pressure in U.S. mitral valve within Structural Heart persists, delaying the recovery to mid-to-high single-digit growth beyond expectations.
• Growth in Diabetes Care and the CGM market continues to slow, or Abbott's share pressure versus Dexcom worsens.
• The drag from China VBP on Core Lab international business fails to moderate to the mid-single digits as expected.
• Nutrition recovers more slowly than planned and cannot return to its historical 2%-4% growth range in 2027.
• Declines in Rapid and Molecular Diagnostics due to weak respiratory testing demand continue.
• Progress on new products, reimbursement expansion, or regulatory approvals falls short of management expectations, including Libre Duo, TactiFlex Duo, Amulet 360, and IVL-related products.

What to watch

• Whether 2H26 comparable sales growth accelerates toward about 8.7%.
• The actual contribution from the four growth buckets of Nutrition, Electrophysiology, Core Lab, and Cancer Diagnostics.
• Whether U.S. hospital procedure volumes, Core Lab testing volumes, and Diagnostics testing volumes continue to support the view of resilient healthcare demand.
• Improvement in U.S. commercial execution for Structural Heart in Q3 and Q4.
• CGM reimbursement catalysts, including CMS T2D non-insulin coverage and expanded international basal-only coverage.
• Progress in the EP product pipeline, including the full rollout of Volt 2.0 and approvals for TactiFlex Duo and Amulet 360.
• Growth in Cologuard new users, repeat screening users, and care gap programs within Cancer Diagnostics.
• Whether FY26 EPS guidance still has room for further upward revision.